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A B S T R A C T
Osteosarcoma is themost common type of bone cancer, especially in children and young adults. The primary
treatment for osteosarcoma is a combination of surgery and chemotherapy, however prognoses remain
poor due to chemoresistance and early metastases. Osteosarcoma stem cells appear to play central roles
in tumor recurrence, metastases and chemoresistance via self-renewal and differentiation. Targeting these
cells may provide a novel strategy in the treatment of osteosarcoma. This review summarizes current
knowledge of this rare phenotype and recent advances in understanding the functions OSCs (osteosar-
coma stem cells) in osteosarcoma, with the aim of improving therapies in the future.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Osteosarcoma is the most common type of bone cancer and the
second leading cause of cancer-related deaths in children and young
adults [1]. Themajority of osteosarcomas originate in the long bones,
such as the distal femur and proximal tibia. It is highly aggressive
with a metastatic rate of ~20%, with the most common targets being
the lung and other bones [2]. Although the origins of osteosar-
coma remain unclear, the most likely candidates are considered to
be mesenchymal stem cells (MSCs) or osteoprogenitor cells [3,4].
Currently, the primary treatment for osteosarcoma is a combina-
tion of surgery and chemotherapy. However, osteosarcoma frequently
develops resistance to conventional chemotherapies resulting in
tumor recurrence. Amputation of the affected limbs is often the only
option but even this usually fails to save a patient’s life due to early
metastases [5]. A better understanding of tumor pathology in os-
teosarcoma and the mechanisms of initiation and recurrence are
urgently needed to improve patient prognosis.
Discovery of osteosarcoma cancer stem cells
Emerging evidence has indicated that malignant tumors contain
a hierarchy of cells responsible for tumor initiation, propagation,
recurrence and resistance to therapy [6]. These include a rare phe-
notype termed cancer stem cells (CSC), that have the ability to retain
their stem cell-like properties through self-renewal and differen-
tiation [7]. CSCs are generally more malignant than differentiated
cancer cells and may present a precise therapeutic target that cir-
cumvents conventional treatments to the tumor bulk. Elucidating
the role of CSCs in osteosarcomamay improve prognosis in the treat-
ment of osteosarcoma [8,9].
The existence of OSCs (Osteosarcoma stem cells) was ﬁrst dem-
onstrated by Gibbs et al. who identiﬁed a subpopulation of cells in
human osteosarcoma tissue samples and cell lines that were capable
of growing sarcospheres, or osteospheres, in serum-free condi-
tions [10,11]. Martins-Neves et al. identiﬁed a subpopulation of cells
inMNNG/HOS osteosarcoma cell lines that showed resistance to che-
motherapeutic agents and irradiation and exhibited stem-like
properties [12]. Other in vitro studies supporting the existence of
OSCs included the formation of sarcospheres in MG63 cells under
anchorage-independent conditions [13] and isolation and charac-
terization of OSCs in human and canine osteosarcoma [14].
Side population (SP) cells have also been identiﬁed in osteosar-
coma. These exhibit increased sphere-forming and colony formation
capabilities and higher tumorigenicity compared to non-SP cells [15].
This was conﬁrmed by Yang et al. who demonstrated that only the
SP fraction had the capacity to self-renew [16].
Research now focuses on the regulatory mechanisms that un-
derlie OSC initiation and activities and their potential as therapeutic
targets in the treatment of osteosarcoma [1,8,11].
Techniques to isolate osteosarcoma stem cells
Surface markers, such as CD133, are commonly used to identi-
fy CSCs; however their biological function in osteosarcoma is unclear
and suitable markers for separating OSCs from differentiated cells
* Corresponding author. Tel.: +86 023 68755641; fax: +86 023 68755641.
E-mail address: qiaonan85@263.net (Q.-N. Guo).
http://dx.doi.org/10.1016/j.canlet.2015.11.003
0304-3835/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Cancer Letters 370 (2016) 268–274
Contents lists available at ScienceDirect
Cancer Letters
journal homepage: www.elsevier.com/ locate /canlet
remain to be found [17]. Gemei et al. detected 50 out of 245 mem-
brane proteins that were differentially expressed between OSCs and
differentiated cells through gene expression proﬁling. Their results
have provided valuable data towards deﬁning a cell-surface protein
signature for OSC [18].
Fig. 1 provides a schematic illustration of these markers in OSCs;
Table 1 summarizes their functions.
CD133
CD133 (AC133), a member of prominin family, is a glycopro-
tein with 3 isoforms that has been wildly used for isolating CSCs.
Several studies have linked CD133-positive cells with a stem-cell
phenotype. These include CD133-positive subpopulations exhibit-
ing stem-like properties in SAOS2, MG63 and U2OS osteosarcoma
cell lines [19–21]; elevated mRNA expression levels in stemness
genes Oct4, Nanog and CXCR4 [22,23]; higher migration and inva-
sive capabilities, particularly in lung metastasis [24]; and increased
drug resistance [22,23]. In addition, cell populations with el-
evated levels of CD133 and CD199, along with low levels of CD44,
exhibited higher levels of stem cell markers [25]; and CD49f-
negative/CD133-positive cells possessed strong tumorigenicity and
self-renewal capacities and were able to differentiate to CD49f-
positive cells with more limited tumorigenicity [26].
CD117 and Stro-1
CD117 and Stro-1 are MSC markers. They have been found to
be preferentially expressed in spheres and doxorubicin-resistant
osteosarcoma cells and CD117-Stro-1 double-positive OSCs have
been identiﬁed in both human and murine osteosarcoma cells
and were found to exhibit high degrees of multipotency, invasive-
ness, drug resistance and elevated levels of self-renewal and
metastatic potential [27]. Furthermore, they were enriched in
metastasis-associated marker CXCR4 and drug-resistance marker
ABCG2 [27]. Adhikari et al. also showed them to be highly effec-
tive in forming transplantable tumors. In contrast, CD117-Stro-1
double-negative cells lacked this ability [27]. Several studies have
conﬁrmed these ﬁndings [35,36,54], demonstrating the impor-
tance of CD117 and stro-1 as molecular markers for identifying
and isolating OSCs in osteosarcoma. CD105 and CD44 have also
been identiﬁed as effective MSC markers in osteosarcoma along
with CD117 and stro-1 [10].
Other molecular markers
Other molecular markers that are associated with the OSC phe-
notype include the following: enhanced aldehyde dehydrogenase
(ALDH) activity has been linked to increased levels of tumorige-
nicity, self-renewal and differentiation potential in osteosarcoma cell
lines [28]; increased expression of ATP-binding cassette sub-
family Gmember 2 (ABCG2) and tumormetastasis-associatedmarker
CXCR4 have both been reported in sphere cells [16,24,27]; CD271,
a marker of MSCs and humanmelanoma cancer stem cells, was able
to distinguish a subpopulation of osteosarcoma cells that dis-
played stem-like features such as self-renewal, drug resistance and
tumorigenicity [31]; and hematopoietic and MSC antigen Sca-1 was
identiﬁed as an effective OSCmarker [29,30]. Lower expression levels
of CD326, CD24, CD44 and CBX3 have been identiﬁed in sarcospheres
associated with the OSC phenotype, suggesting that ABCA5 may be
a putative biomarker for OSCs [55].
Side population cells
Side population (SP) cells exhibit high levels of multidrug re-
sistance and share similarities with CSCs. For example, SP cells have
been linked to ABC protein transporters with high expressions of
stemness genes Oct4 and Nanog [16]. The long-term label reten-
tion dye pKh26 can differentiate between rapidly dividing cells and
quiescent cells, and studies using pKh26hi have identiﬁed SP cells
as a subpopulation capable of self-renewal and tumor generation
[32]. Hoechst dye exclusion assays are a commonway to isolate drug-
resistant cells and thereby establish SP cells [17].
Fig. 1. Molecular markers used to isolate OSCs in tumors. The schematic diagram illustrates the functional roles of three key pluripotent molecules Oct3/4, Sox2 and Nanog
and associated markers commonly used to identify OSCs.
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Signaling pathways that inﬂuence osteosarcoma stem cells
The roles of signaling pathways, epigenetic regulators and the
microenvironment in the regulation and maintenance of OSCs are
illustrated in Fig. 2 and summarized in Table 1.
Oct3/4, Sox2 and Nanog
Transcription factors Oct3/4, Sox2 and Nanog play central roles
in the development of CSCs in a variety of tumors and maintaining
pluripotency and self-renewal in undifferentiated embryonic stem
cells [56–61], and have been used to establish stemness in OSCs
[10,16,19,21,31]. Levings et al. engineered an osteosarcoma cell line
that stably expressed humanOct4 promoter-driven GFP reporter gene
andwere signiﬁcantlymore tumorigenic than GFP-depleted cells. The
Oct4/GFP+ cells also expressedMSCmarkers CD105 and ICAM-1 and
had a propensity to metastasize to the lung [33]. Sox2 was highly ex-
pressed in both human andmurine osteosarcoma cell lines and tissue
samples. Knockdown of Sox2 resulted in increased differentiation in
osteosarcoma cells and a reduction in clone formation, migration and
invasion, while activating the Wnt pathway and thereby inhibiting
tumor formation. In contrast, Sox2-depleted osteosarcoma cells failed
to form osteospheres and differentiated intomature osteoblasts [29].
These observations were conﬁrmed by Tang et al. who also showed
that overexpression of Oct4 and Sox2 led to an enrichment of tumor
stem cells in osteosarcoma cell lines [34]. Less is known about the
actions of Nanog in osteosarcoma, however studies have indicated
that it may target CSCs [62]. Our previous study indicated that sup-
pression of Nanog, through overexpression of TSSC3 (PHLDA2),
inhibited the OSC phenotype in osteosarcoma cell lines [35].
TGF-β1
Transforming growth factor β1 (TGF-β1) is a pleiotropic cytokine
that promotes tumor propagation and cytokine secretion [63]. TGF-
β1 signaling combined with a hypoxic environment dramatically
induced self-renewal in non-stem osteosarcoma cells and in-
creased metastatic potential, chemoresistance, tumorigenicity and
neovasculogenesis in OSCs [36]. It was suggested that osteosar-
coma cells may secrete TGF-β to maintain MSC stemness and
promote production of pro-tumor cytokines [37]. TGF-β1 treat-
ment has also been linked to expression of Sox2 in immature or
undifferentiated cells, and to a marginal increase in expressions of
Nanog and Oct4 [36].
BMP-2
BMP-2 is an active inducer of osteoblastic differentiation in im-
mature osteoblasts and less committed cells. Reports have implicated
BMP-2 in the induction of tumorigenic factors and the proliferation
and aggressiveness of osteosarcoma MSCs (OSMSC) [38]; and ele-
vation of BMP-2 has been linked to overexpression of VEGF, EMMPRIN
andMMP-9 in OSMSCs [38]. In contrast, researchers reported BMP-2
downregulated Oct3/4, Sox2 and Nanog expression in osteosar-
Table 1
Summary of ﬁndings in OSC research.
Speciﬁc Findings Reference
Markers CD133 Over-expressing Sox2, Nanog, Oct4, Nestin, CXCR4 [19–26]
Tumorigenic, differentiable, side-population, drug-resistance
Migrative, invasive and higher lung metastasis rate
CD199+, CD44−, CD49f−
CD117 and Stro-1 Tumorigenic and multipotent [10,27]
Invasive, metastatic, self-renewal, drug resistant
Over-expressing CXCR4, ABCG2, CD105, CD44
ALDH Tumorigenic, self-renewal, differentiable [28]
ABCG2 and CXCR4 Sphere-forming [16,24,27]
Sca-1 Related to Sox2 and Wnt pathway [29,30]
Sphere-forming, differentiable
CD271 Self-renewal, drug resistant and tumorigenic [31]
Side population Multidrug resistance, self-renewal, tumorigenic, sphere-forming [15–17]
Over-expressing Oct4 and Nanog
pKh26 Self-renewal, tumorigenic [32]
Regulators Oct3/4 Tumorigenic and metastasis, expressing CD105 and ICAM-1 [33]
Sox2 Sphere-forming, differentiable, invasive, tumorigenic [29,34]
Repress Wnt pathway
Nanog Repress by TSSC3 [35]
TGF-β Related to hypoxia, self-renewal, metastatic, chemoresistant [36,37]
Tumorigenic, neovasculogenesis, supporting neighboring MSCs
Induce Sox2, Oct4, Nanog,
BMP-2 Over-expressing VEGF, EMMPRIN, MMP-9, tumorigenic [38]
Decrease of Nanog, Oct4, Sox2 [39]
Decrease of tumorigenicity and proliferation
MAPKs Invasive and migrative, tumorigenic, undifferentiated [18,40]
Activate by TNFα and IL-1
Notch Tumor initiation, propagation, aggressive [41–44]
Regulate ALDH expression
Hedgehog Tumor initiation, regulate Yap1 and H19 [45–47]
Epigenetical regulators TSSC3 Reduce self-renewal, cell vitality, induce apoptosis [35,48]
Decrease of Oct4, Sox2, Nanog
HIF2PUT Decrease CD133, sphere-forming [49]
miR-133a Invasive and aggregative [50]
let-7/98 and miR-29a,b,c Microarray analysis [51]
miR-29b-1 Reduce growth and sphere-forming [52]
Repress CD133,Oct4, Nanog, Sox2
Telomerase Sphere-forming, invasive, chemoresistant, tumorigenic [53]
Over-expressing CD117 and Stro-1
MLH1 and MSH2 Chemoresistant and sphere-forming [13]
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coma cells and upregulated transcription of osteogenic markers
Runx-2 and Collagen Type I, resulting in decreased tumorigenicity
[39], and BMP-2 expression has been linked to decreased expres-
sion of ki67, potentially inhibiting the proliferation of OSCs [39].
MAPK pathway
Mitogen-activated protein kinases (MAPK) play key roles in many
cellular programs, including cell proliferation, differentiation, mo-
tility and survival [64], and studies have indicated theymay inﬂuence
the OSC phenotype: MAPK signaling has been linked to cytoskeletal
rearrangement during tumoral invasion in osteosarcoma cells; and
the ERK/MAPK pathway has been associated with differentially ex-
pressed proteins involved in the enhanced invasiveness andmotility
of OSCs [18]. ERK activation of TNFα and IL-1 was implicated in
maintaining AX cells, a OSC cell line, in an undifferentiated state,
thereby promoting tumor progression and reducing osteoblastic gene
expression [40].
Notch and Hedgehog pathway
Notch proteins are transmembrane receptors activated by ligands
on adjacent cells. Following activation, the Notch intracellular domain
(NICD) is released and enters the nucleus where it regulates ex-
pressions of Hey and Hes family proteins. These are involved in the
maintenance of stem cells [65]. Dysregulation of Notch signaling
was shown to result in osteosarcoma, demonstrating the signiﬁ-
cance of Notch signaling in the initiation and progression of
osteosarcoma [41,42]. Furthermore, cell lines derived from Notch-
induced osteosarcoma formed aggressive high-grade-type tumors
in nude mice; and Notch-activated mutation acted as a second hit
in a p53-loss-driven osteosarcoma model, signiﬁcantly shortening
tumor latency and aggressiveness [43]. Meanwhile, both the ag-
gressive metastatic phenotype and ALDH activity were reduced in
a murine osteosarcoma cell model following inhibition of Notch sig-
naling. This ﬁnding suggests that Notch signalingmay inﬂuence OSCs
via suppression of ALDH [44]. Hedgehog pathways have been shown
to participate in the regulation of CSCs in a variety of tumors, in-
cluding glioblastoma [66,67] andmelanoma [68]; furthermore, they
have been implicated in the initiation and regulation of OSCs [45].
Hedgehog signaling regulates the expressions of downstream genes
by activating GLi through membrane receptors, such as PTCH and
Smoothened [69]. Recent reports have shown that Hedgehog is
overexpressed in osteosarcoma cell lines; however, cell growth could
be suppressed through inhibition of Smoothened [46]. Conﬁrma-
tion of the role of Hedgehog signaling in osteosarcoma development
was demonstrated in a mouse model: aberrant Hedgehog signal-
ing in mature osteoblasts via Yes-associated protein 1 (Yap1) and
H19 led to the development of osteoblastic osteosarcoma [47].
Epigenetic regulators in osteosarcoma stem cells
Imprinting gene TSSC3
Genomic imprinting is the epigenetic modiﬁcation of gene loci
resulting in altered allelic expression. A malignant-transformed
Fig. 2. The roles of signaling pathways, epigenetic regulators and the microenvironment in the maintenance of OSCs. Although the regulatory mechanisms of Oct3/4 and
Sox2 in stemness have been studied extensively, the role of Nanog in OSCs remains largely unexplored. Key regulatory pathways in the initiation of OSCs include Notch and
Hedgehog; MAPK-related pathways have been associated with invasiveness and motility in OSCs; additional pathways are described in the text. The epigenetic imprinting
gene TSSC3 is considered to facilitate OSCs in evading apoptosis via inhibition of Akt; telomerase is reported to promote self-renewal; whereas, hypoxia may induce TGF-β1
expression and promote self-renewal. The stem cell niche may provide a microenvironment for OSCs to maintain stemness and generate differentiated progeny.
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osteosarcoma cell line (MTF) has been developed in our laborato-
ry composed primarily of OSCs capable of forming spheres [70].
Microarray analysis identiﬁed 10 imprinting genes that were
aberrantly expressed, including tumor-suppressing STF cDNA 3
(TSSC3) in this cell line. This imprinting gene is related to cell death
and was signiﬁcantly downregulated [70]. Overexpression of TSSC3
has also been reported to suppress cell vitality and growth, induce
apoptosis and downregulate expressions of Oct4, Sox2 and Nanog
in osteosarcoma cells, leading to dramatic reductions in the OSC phe-
notype [35,48].
MicroRNAs
MicroRNAs (miRNA) have been implicated in the epigenetic reg-
ulation of cancer cells and the followingmiRNAs have been identiﬁed
in tumor-related functions in osteosarcoma. Hypoxia-inducible factor-
2α (HIF-2α) promoter upstream transcript (HIF2PUT) is a novel long
non-coding RNA (lncRNA); overexpression of HIF2PUTmarkedly de-
creased the percentage of CD133-expressing cells and impaired OSC
sphere-forming capacity in MG63 osteosarcoma cells [49]. Silenc-
ing miR-133a reduced cell invasion and prolonged survival in
osteosarcoma-bearing mice, suggesting that miR-133a may play a
role in OSC regulation [50]. A total of 189 miRNAs were reported
to be differentially expressed in 3AB-OS CSCs relative to their pa-
rental cells. These included two miRNA families, let-7/98 and miR-
29a, b, c, and their anticorrelated mRNAs (MSTN, CCND2, Lin28B,
MEST, HMGA2 and GHR), suggesting theymay comprise a set of OSC
markers [51]. MiR-29b-1 was found to negatively regulate expres-
sions of CD133, N-Myc, Oct3/4, Sox2 and Nanog in OSCs; in contrast
overexpression of miR-29b-1 consistently reduced growth and the
sphere-forming ability of OSCs in this cell line [52].
Telomerase and DNA repair
Telomerase activity has been detected in most malignant cancer
cells, including osteosarcoma, and is crucial for the maintenance of
stem/progenitor cells. However the relationship between telomerase
expression and CSCs remains unclear [71]. High telomerase activ-
ity has been linked to enhanced stem cell-like properties in
osteosarcoma cells, including sphere-forming capacity, invasive-
ness, metastatic potential and resistance to chemotherapeutic agents
[53]. In addition, sphere-driving OSCs displayed increased expres-
sions of CD117 and Stro-1 compared to telomerase-negative cells;
conversely inhibition of telomerase resulted in decreased tumori-
genic potential in osteosarcoma [53]. Increased expression of DNA
repair enzyme genes, MLH1 and MSH2, has also been linked to che-
moresistance in osteosarcoma sphere cells [13].
Microenvironment of osteosarcoma stem cells
Stem cell niche deﬁnes themicroenvironment in which stem cells
reside. It is comprised of stem cells, neighboring supportive cells,
inﬂammatory cells, microvessels, the extracellular matrix and soluble
factors such as chemokines and cytokines. The niche microenvi-
ronment facilitates stem cells in entering quiescence and undergo
differentiation and to maintain their stemness including self-
renewal and to regulate differentiation [72,73]. This has been
demonstrated in OS99-1 cells: OS99-1 cells with high ALDH activ-
ity exhibited CSC-like behavior when the cells were isolated from
subcutaneous tumors in vitro and not from adherent cultures [28].
Three types of stem cell microenvironments have been reported in
glioblastoma: perivascular niche, hypoxic niche andmetastatic niche.
Tumor stem cells are thought to induce vascularization and differ-
entiate into endothelial-like cells to mimic microvessels in order
to supply oxygen and nutrition to the tumor [74,75]. GSCs (Glio-
blastoma stem cells) have been found adjacent to capillaries and
adhered to endothelial cells in brain tumors [76]. This was further
demonstrated through increased tumor formation in mice follow-
ing co-injection of CD133-positive human medulloblastoma cells
with endothelial cells [76]. Further investigation revealed that the
process was mediated by VEGF/VEGFR and SDF-1/CXCR4 path-
ways [77,78]. Osteosarcoma is a tumor enriched in vasculature,
supporting the existence of a perivascular OSC niche, and reports
have conﬁrmed that the hypoxic niche is central in osteosarcoma
propagation and CSCmaintenance [79,80]. Hypoxia-inducible factor
(HIF) has been reported as highly expressed in CSCs in several
tumors; conversely, blocking HIF-1α or HIF-2α activity resulted in
dramatic decreases in CSC proliferation and self-renewal [81]. A
hypoxic environment in non-stem osteosarcoma cells has been re-
ported to dramatically induce the self-renewal capacity of OSCs [36].
Interestingly, expression of the epigenetic gene TSSC3, which is also
known as PHLDA2, reported to repress OSC self-renewal, can be regu-
lated by hypoxia [82]. Both the Notch and Hedgehog pathways have
been implicated in the stem cell niche: The Notch pathway was re-
ported to be activated and to promote stem-like characteristics in
glioblastoma and colorectal cancer. This was believed to be through
Nitric oxide and Notch ligands released from tumor endothelial cells
in the stem cell niche [83–85]; the Hedgehog pathway was acti-
vated in the glioblastoma stem cell (GSC) niche, probably through
ligands secreted by endothelial cells, suggesting a paracrined func-
tion may support CSCs [6]. Although there is few data for
understanding microenvironment of OSCs, it is without doubt that
microenvironment could notably inﬂuence the biological behav-
iors of OSCs. Exploration of molecular interactions among OSCs,
microvessels and hypoxia in future might develop new therapeu-
tic strategy to target OSCs.
Therapeutic targeting of osteosarcoma stem cells
CSCs exploit various mechanisms to deregulate apoptotic sig-
naling pathways, including the ability to enter quiescence and slow
the rate of proliferation [86]. This can be combined with
overexpression of ABC drug eﬄux transporters to enhance chemo-
resistance [87]. Inhibition of drug eﬄux transporters was found to
enhance cellular uptake of doxorubicin and initiate apoptosis in OSCs;
whereas, eﬄux activity of drug transporters P-glycoprotein and
breast-cancer related proteins facilitated OSCs entering quies-
cence through activation of anti-apoptotic mediators Bcl-2 and Bcl-
xL, downregulation of Bak, and caspase-3/7 inactivation [88]. The
anticancer agent salinomycin has been shown to be an effective in-
hibitor of OSCs in vivo and in vitro. Salinomycin inhibited expressions
of Oct4 and Sox2 and suppressed the sphere-forming capacity and
chemoresistance in OSCs without severe side effects. Salinomycin
can inhibitWnt pathway activity suggesting the involvement of Wnt/
β-catenin signaling [34]. Bufalin is the active component in the
Chinese medicine Chan Su. Bufalin treatment of immunodeﬁcient
mice and OSCs derived from the MG63 cell line resulted in their in-
ability to differentiate. Further investigation revealed the expression
of stem cell markers CD133 and Oct4. Treatment with bufalin also
inhibited sphere forming and proliferation in these cells [25].
Signaling pathways associated with OSC niche functions may
present novel targets for the treatment of osteosarcoma: studies have
shown that the Hedgehog and Notch pathways participate in the
perivascular niche; and VEGF/VEGFR and SDF-1/CXCR4 contrib-
uted to angiogenesis and reprograming of endothelial cells in the
GSC niche. Conversely, anti-VEGF and CXCR4 could suppress tumor
angiogenesis and may break down the perivascular niche.
TSSC3 is an imprinting gene that is primarily regulated by meth-
ylation. As reported above, expression of TSSC3 was found to be
signiﬁcantly lower in OSCs than in differentiated osteosarcoma cells;
conversely overexpression of TSSC3 could increase apoptosis and
inhibit drug resistance in OSCs [35]. These ﬁndings suggest that
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TSSC3 expression in osteosarcoma could be targeted by
demethylation drugs. MST312 [53] and caffeine are telomerase and
DNA repair inhibitors, respectively, suggesting theymay also be can-
didates for OSC-targeted therapies [13]. Telomerase is partially
responsible for immortalization in malignant tumor cells, and el-
evated telomerase activity has been implicated in self-renewal and
chemoresistance in OSCs [89]; caffeine enhanced the eﬃcacy of doxo-
rubicin and cisplatin, indicating that drug resistance in sarcosphere
cells was related to an eﬃcient DNA repair capacity in OSCs. Other
potential therapeutic agents for TSC (Tumor stem cells) ablation in
osteosarcoma include the epigenetic regulator (5-azacytidine), anti-
microtubule drug (vincristine) and telomerase inhibitor (RHPS4) [55].
Conclusion
Cancer stem cells have been implicated in malignant tumor ini-
tiation, recurrence, drug resistance, invasion and metastasis.
Therefore therapeutic targeting of OSCs offers a promising strate-
gy for the treatment of osteosarcoma. However, such treatments
require accurate identiﬁcation and isolation of OSCs. Currently, the
most effective markers for OSCs are CD133, CD117, Stro-1 and ALDH.
Although each of these have displayed partial success in isolating
CSCs in other types of cancer [90–92], a deﬁnitive set of markers
that can speciﬁcally isolate OSCs remains to be found. It may be pos-
sible to improve the eﬃciency and accuracy of OSC-isolation by
combining CSC markers with sphere-forming assays and SP cell
sorting. However, sphere-forming and SP subpopulations are not
exclusively comprised of CSCs, resulting in an overlap of cell types
[93]. Therefore, further research is required to fully understand the
biological functions of CSC markers in order to accurately isolate
OSCs from non-OSCs.
There has been increasing interest in the key signaling path-
ways involved in CSC actions with the aim of developing new
therapies to target CSCs. However, relatively few studies have focused
on OSCs. The roles of TGF-β1, Sox2 and Notch pathways in the ini-
tiation and regulation of OSCs have attracted the most attention and
the ﬁndings have been promising. Recent research into epigenetic
intervention has also been encouraging, particularly in relation to
the imprinting gene TSSC3 and the effects of demethylation drugs
in OSCs. The OSC niche and the inﬂuence of the microenviron-
ment in situ may provide an alternative approach to elucidate the
events that contribute to OSC generation and regulation.
Despite recent advances, much of the research into OCSs has
focused on individual functions or mechanisms and studies have
not been correlated. Further development will require systematic
and in-depth understanding of the molecular mechanisms that un-
derlie regulation and maintenance of the OSC phenotype and its
inﬂuence in osteosarcoma in order to improve patients’ prognoses.
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